PreludeDx™ Announces Novel Test for Predicting Radiation Therapy Benefit and Recurrence Risk in Early-Stage Invasive Breast Cancer Patients

LAGUNA HILLS, Calif., March 14, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics, has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast™ – a novel biosignature that predicts 10-year recurrence rate…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks